| 摘要 |
<p>Disclosed are fusion polypeptides that include an IL-12 p40 subunit polypeptide covalently linked to an enzymatically inactive polypeptide. The fusion polypeptides have an increased in vivo half-life relative to the native IL-12 p40 subunit. The fusion polypeptides function as antagonists of the IL-12 receptor, and can be used, for example, as immunosuppressive agents (e.g., in treating autoimmune diseases or in inhibiting graft rejection) or to treat or prevent endotoxin-induced shock.</p> |
